This Biotech Stock Just Gapped Up To A Five-Year High; Here's Why

On Thursday, Omeros stock reached a peak not seen in five years following exceptional second-quarter results for its latest treatment addressing transplant complications. The surge in stock value is attributed to the successful performance of the new treatment in the market.